ライフサイエンスコーパス: GP

1 GP activities acting on beta-(1->3)-glucooligosaccharide

2 GP cells showed cytoplasmic microvacuolization and apopt

3 GP outcomes included attitudes, knowledge, confidence, a

4 GP-5 (Glycoprotein V), GRN (granulin), and MCAM (melanom

5 GPs in control practices did not receive specific traini

6 GPs in the intervention practices were trained in the FR

7 GPs underwent immunohistochemical staining for TRPV1.

8 In addition to exploring each of the 1286 GPs, the website contains GPs pre-calculated for a repre

9 tial viral migration patterns in 8 FCs and 2 GP cohorts and a Bayesian phylogenetic inference in BEAS

10 rvention group and 99 (99%) patients from 25 GPs in the control group were included in the primary ou

11 We identified 27334 GP consultations and >5 million emergency hospital admis

12 s; 34 GPs) or control group (4 practices; 29 GPs).

13 A total of 122 (97%) patients from 32 GPs in the intervention group and 99 (99%) patients from

14 a 1:1 ratio to intervention (4 practices; 34 GPs) or control group (4 practices; 29 GPs).

15 was rated by the TDL-BAAM model as well as a GP-based deep learning model (GPDL-BAAM) and two pediatr

16 London's Whittington Hospital created a GP with Special Interest (GPwSI) community paediatric al

17 ing status, previous negatives and whether a GP had ordered a blood test.

18 e the fact that the same mutations abolished GP processing and membrane fusion in a plasmid-based pro

19 ubstitutions at conserved residues abolished GP processing and membrane fusion in plasmid-transfected

20 activates PhK, which inhibits GS, activates GP and moves it toward the SR, favoring glycogenolysis.

21 y how small-molecule entry inhibitors affect GP stability.

22 t into smaller sets of features and allowing GP to select the best subset in the final pipeline.

23 s most prevalent in the FCs (115, 45.1%) and GP (177, 50.4%).

24 rning (ANN, SVM, RF, ExtraTrees, Bagging and GP) and computational chemistry.

25 cluded attitudes, knowledge, confidence, and GP LBP management behaviour.

26 markers between the developmental delay and GP groups.

27 genetic enrichment, the risks in the FDR and GP children converged but were not identical for multipl

28 redox-associated markers 8-OHdG, GADD45 and GP-1 were also detected within isolated bulbar melanocyt

29 Ratios of DN to pons and GP to CA were calculated, and univariable Pearson correl

30 ines through the SST1, SST2, SBTI, SBTII and GP sensilla.

31 e) at 3 months adjusted for baseline SFA and GP practice using intention-to-treat analysis.

32 RTX decreases sympathetic and GP nerve activity, abolishes apnea's electrophysiologica

33 Antibodies against VP40 and GP are found to predominate and two protective antigenic

34 s, a diverse IgM repertoire against VP40 and GP epitopes is observed suggesting occult viral persiste

35 Anti-GP mAbs targeting membrane proximal epitopes or the GP m

36 unction of mAbs to EBOV GP, we selected anti-GP mAbs targeting representative, protective epitopes an

37 trast to previous studies, we find that anti-GP mAbs exhibited differential requirements for FcgammaR

38 reticulum (SR) junctional cisternae, and apo-GP at Z disk.

39 Viral entry is mediated by the arenavirus GP complex, which consists of the stable signal peptide

40 -BAC mice, alpha-GA(1) reduced GA as well as GP and GR proteins, improved behavioral deficits, decrea

41 In conclusion, the ePlex BCID-GP Panel compares favorably to SOC and targeted molecula

42 ared the investigational-use-only (IUO) BCID-GP Panel to other methods of identification of 20 Gram-p

43 d Culture Identification Gram-Positive (BCID-GP) Panel is a multiplex nucleic acid amplification assa

44 Negative targets that are unique to the BCID-GP Panel.

45 clinical and contrived samples with the BCID-GP Panel.

46 and 565 contrived) were tested with the BCID-GP Panel.

47 demonstrates that AF screening performed by GP practice-based pharmacists was feasible, economically

48 ation in which the monomers are separated by GP lifting or bending.

49 olume of periodontal procedures performed by GPs.

50 Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in

51 construct drives strong expression of CCHFV-GP, in vitro.

52 trates that a rVSV expressing only the CCHFV-GP has the potential to serve as a replication competent

53 Here, we characterized GPs from Gram-positive bacteria and heterokont algae act

54 Cleaved GP then binds its cellular receptor, Niemann-Pick C1.

55 The LASV glycoprotein complex (GP) is a promising target for vaccine or drug developmen

56 rmostability upon cleavage to GP conformers (GP(CL)).

57 g each of the 1286 GPs, the website contains GPs pre-calculated for a representative set of proteomes

58 VD structure with disorganized and decreased GP, EP, and internal AF (IAF), and less compact and mark

59 ly, acid pH enhanced, rather than decreased, GP thermostability, suggesting it could enhance viral su

60 Pegboard-dominant (GP-DH) and non-dominant (GP-NDH) hands] tests.

61 o motor function [Grooved Pegboard-dominant (GP-DH) and non-dominant (GP-NDH) hands] tests.

62 Specific binding of hGal-3C to each GP was successfully detected by CaR(IMS)-ESI-MS; no bind

63 gnificant increase in the frequency of Ebola GP-specific CD4 and CD8 T cell responses.

64 EBOV GP vaccine with Matrix-M adjuvant is well tolerated and

65 ted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or w

66 All EBOV GP vaccine formulations were well tolerated.

67 safer than a parallel construct with an EBOV GP lacking the MLD (VSV-EBOVDeltaMLD).

68 djuvant showed a rapid increase in anti-EBOV GP IgG titers with peak titers observed on Day 35 repres

69 djuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on

70 ination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no eviden

71 hibitors of filovirus entry destabilize EBOV GP and uncovered evidence that the most potent inhibitor

72 -fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which

73 -fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which

74 with cleaved Ebola virus glycoprotein (EBOV GP(CL)) reveals that binding of the mAb structurally mim

75 chimeric VSV expressing the full-length EBOV GP (VSV-EBOV) containing the MLD was substantially more

76 Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, thereby

77 We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-

78 Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP

79 Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP

80 s the conserved interaction between the EBOV GP core and its glycan cap beta17-beta18 loop to inhibit

81 ated as a vaccine vector to express the EBOV GP gene.

82 monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when adminis

83 The mucin-like domain (MLD) of the EBOV GP may enhance virus immune system evasion.

84 Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here co

85 y to the protective function of mAbs to EBOV GP, we selected anti-GP mAbs targeting representative, p

86 ess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to containment

87 ere, we compared chimeric VSVs in which EBOV GP replaces the VSV glycoprotein, thereby reducing the n

88 , seroconverted against both RABV-G and EBOV-GP.

89 ynthetic anti-Ebola virus glycoprotein (EBOV-GP) DNA vaccines as a strategy to expand protective brea

90 In parallel, we observed that EBOV-GP DNA vaccination induced long-term immune responses in

91 Multiple-injection regimens of the EBOV-GP DNA vaccine, delivered by intramuscular administratio

92 structures by the cocktail enabled enhanced GP binding and virus neutralization.

93 r numbers of referrals from more experienced GPs.

94 e and glycan cap subdomains of all filovirus GPs tested suffered a concerted loss of prefusion confor

95 glycoproteins, including those of filovirus GPs, has provided insights into their propensity to unde

96 mpared with control (difference adjusted for GP practice and baseline: BS versus control = -0.33% [95

97 lian randomization-inferred associations for GP-5, GRN, and MCAM.

98 on seasons, 2017-2018 and 2018-2019, in four GP practices in Kent, United Kingdom.

99 The richer data available from GP databases could be used to complement screening refer

100 ESI-MS), is employed to rapidly identify GBP-GP binding in solution.

101 with the exception of the Cepheid GeneXpert GP assay.

102 viously, we characterized beta-(1->3)-glucan GPs from bacteria and E. gracilis, leading to their clas

103 bodies predominate to VP40 and glycoprotein (GP).

104 odominant NiV receptor-binding glycoprotein (GP), and potently neutralizes NiV, indicating its potent

105 telet adhesion is initiated by glycoprotein (GP)Ib and GPIIbIIIa receptors on the platelet surface bi

106 cross-reactive with both Ebola glycoprotein (GP) and with the secreted GP (sGP) form.

107 relatedness of the ebolavirus glycoprotein (GP) used in all candidate vaccines against these viruses

108 tively bound to the ebolavirus glycoprotein (GP).

109 d was able to express the EBOV glycoprotein (GP) gene at high level.

110 es (mAbs) that target the EBOV glycoprotein (GP) have demonstrated potent protective activity in anim

111 Human anti-EBOV Glycoprotein (GP) IgG titers were measured using a commercially availa

112 irus (VSV) expressing the EBOV glycoprotein (GP) might selectively target brain tumors.

113 genicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matr

114 genicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matr

115 of inhibition of LASV and EBOV glycoprotein (GP)-bearing pseudoviruses; three (clomiphene, sertraline

116 inhibitor, via binding to EBOV glycoprotein (GP).

117 ressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-1

118 he Ebola virus (EBOV) envelope glycoprotein (GP) is a membrane fusion machine required for virus entr

119 all utilize the sole envelope glycoprotein (GP), do not protect against heterologous ebolaviruses.

120 e granule secretion machinery, glycoprotein (GP) VI, or the GPVI signaling effector phospholipase C (

121 h rVSV vectors expressing MARV glycoprotein (GP) 20-30 minutes after a low dose exposure to the most

122 tor binding site (RBS) of MARV glycoprotein (GP).

123 elet-specific surface receptor glycoprotein (GP) VI, using F(ab')(2) fragments to avoid platelet clea

124 cells is mediated by its spike glycoprotein (GP).

125 We produced a panel of SUDV glycoprotein (GP)-specific human chimeric monoclonal antibodies (mAbs)

126 ied in the Ebola virus surface glycoprotein (GP(12)) observed in all 48 genomes, deployed monoclonal

127 ntibodies to the viral surface glycoprotein (GP) are potential correlates of protection.

128 cocktails against the surface glycoprotein (GP) present a potential therapeutic strategy.

129 eutralizing mAbs targeting the glycoprotein (GP) 2 portion of the mucin-like domain (MLD) of MARV GP,

130 In platelets, the glycoprotein (GP) Ib-IX receptor complex senses blood shear flow and t

131 entry is mediated by the viral glycoprotein (GP) complex, which consists of the stable signal peptide

132 ere positively associated with glycoprotein (GP)-specific T-cell but not IgM or IgG antibody response

133 ses (rVSV) expressing foreign glycoproteins (GP) have shown promise as experimental vaccines for seve

134 nd prefusion) versions of the glycoproteins (GP) of lineages II-IV.

135 LP) vaccine that incorporates glycoproteins (GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus

136 to both rabies virus and MARV glycoproteins (GPs) is beneficial for protection in a preclinical murin

137 sifies 91.5%-100% of grandparent-grandchild (GP) pairs, 80.0%-97.5% of avuncular (AV) pairs, and 75.5

138 -20 cm depths from an undisturbed grassland (GP), winter wheat-pea (Pisum sativum L) rotations under

139 Intervention group GP LBP management behaviour became more guideline concor

140 , and confidence compared with control group GPs.

141 Intervention group GPs had improvements in attitudes, knowledge, and confid

142 zed LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP exp

143 tudy suggest that the FREE approach improves GP concordance with LBP guideline recommendations but do

144 e that the QP was associated with changes in GP consultation and hospital admission rates for the sel

145 f 12 conserved residues within the GP2 CT in GP processing, trafficking, assembly, and fusion, as wel

146 A significant decrease in GP consultation rates was estimated for empyema and scar

147 After RTX administration, increases in GP and stellate ganglion activity and blood pressure dur

148 ptibility group, decreasing incrementally in GP children but not in FDR children.

149 gen-positive cells resulted in cilia loss in GP and EP, and disrupted IVD structure with disorganized

150 ure, and the greatest effect was observed in GP.

151 integration of more periodontal services in GP practices as the most likely trends to impact periodo

152 minate and two protective antigenic sites in GP identified.

153 Conclusions Apnea increases GP activity, followed by vagal bursts and tonic stellate

154 In the intervention, GPs were paid a nominal sum for setting up searches of r

155 tter than they neutralized lineage III or IV GP expressing pseudoviruses.

156 prediction tools were used to identify LASV GP B-cell epitopes.

157 putational prediction tools to identify LASV GP major histocompatibility complex (MHC) class I and II

158 olve blocking conformational changes in LASV GP.

159 s infection by authentic LASV, inhibits LASV GP-mediated cell-cell fusion and virus-cell fusion, and,

160 fluenza virus hemagglutinin, stabilizes LASV GP to low-pH exposure.

161 molecular mimicry was a major feature of mAb-GP interactions.

162 iographs is on par with automated and manual GP-based methods for bone age assessment and provides a

163 rtion of the mucin-like domain (MLD) of MARV GP, termed the wing region.

164 e Ab from a MARV-naive donor recognized MARV GP and possessed neutralizing activity against the virus

165 Although our vaccine elicited strong MARV GP antibodies, it did not strongly induce neutralizing a

166 Our work suggests that the MARV GP RBS is a promising candidate for epitope-focused vacc

167 sidue-long HCDR3 loop that bound to the MARV GP the best among the chimeric Abs tested.

168 pecific non-neutralizing mAb, MR235, to MARV GP increased accessibility of epitopes in the receptor-b

169 of these chimerized antibodies bound to MARV GP.

170 that uses GP-specific antibodies to measure GP thermostability under a variety of conditions relevan

171 ease the scope of coverage, we have migrated GPs to function as a companion resource utilizing InterP

172 ver and improve drugs that act by modulating GP stability.

173 ould be extended to include the neighbouring GP for effective epidemic control.

174 ccines developed high levels of neutralizing GP-specific IgG and IgA antibodies.

175 Over the last year, we have added ~700 new GPs, increasing the coverage of eukaryotic systems, as w

176 compared to PADRE's rates of 38.5%-76.0% of GP, 60.5%-92.0% of AV, 73.0%-95.0% of HS pairs.

177 y determines relationship types for 93.5% of GP, 97.7% of AV, and 92.2% of HS pairs that have suffici

178 a; the parent sex in 100% of HS and 99.6% of GP pairs; and it completes this analysis in 2.8 h includ

179 es with both the trimeric bundle assembly of GP and the viral membrane by stabilizing a conformation

180 r studies of filovirus entry, engineering of GP variants with enhanced stability for use in vaccine d

181 study aimed to determine the feasibility of GP practice-based clinical pharmacists to screen the ove

182 al in this model was linked to production of GP-specific antibodies and lower viral load.

183 riments identify key immunodominant sites of GP, while challenge studies in mice found these epitopes

184 The stability of GP at elevated temperatures (thermostability) can provid

185 ional epitopes to measure thermostability of GP embedded in viral membranes.

186 ral coverage through automatic generation of GPs from related resources.

187 ses had better T scores than female cases on GP-NDH, WAIS-IIIDS, WAIS-IIISS, TMT-A, CTT1; better SIP

188 vage and acid pH have significant effects on GP thermostability that shed light on their respective r

189 had significantly lower (worse) T scores on GP-DH, WAIS-IIIDS, Stroop Word-Reading, TMT-A; lower mot

190 ciated with significantly better T scores on GP-NDH, WAIS-IIIDS, Stroop Color-Naming; better motor an

191 gh-affinity human antibodies targeting GA or GP RAN proteins.

192 ctice, and joining with other specialists or GPs to create group practices.

193 1 (Glut-1), and permeability-glycoprotein (p-GP, ABCB1) were similarly significantly higher in the CN

194 mispheric lateralization of globus pallidus (GP) and thalamus (Th) explains individual hemispheric bi

195 n the dentate nucleus (DN), globus pallidus (GP), crus anterior of capsula interna (CA), and pons.

196 Grapefruit (Citrus paradisi) peel (GP) is rich in flavonoids and phenolics which have sever

197 ents a temporal pattern among growth phases (GPs) and vary interannually.

198 Glycoside phosphorylases (GPs) catalyze the phosphorolysis of glycans into the cor

199 Using a Pichinde virus (PICV) GP expression vector and a PICV reverse genetics system,

200 we found presence of cilia on growth plate (GP), cartilage endplate (EP) annulus fibrosus (AF), and

201 nsory neurons within the ganglionated plexi (GP) play a role.

202 s by polar growth from a single growth pole (GP), while the old cell compartment and its old pole (OP

203 is also translated into DPRs, including poly(GP) and poly(PR).

204 We demonstrate that poly(GP) is more abundant in SCA36 compared to c9ALS/FTD pati

205 Interestingly, in SCA36 patient tissue, poly(GP) exists as a soluble species, and no TDP-43 pathology

206 than in children in the general population (GP children).

207 tal delay (n = 140), and general population (GP) controls (n = 378) were analyzed for 42 different im

208 by HIV-1 relative to the general population (GP), the transmission dynamics are not completely unders

209 teins, gram-negative (GN) and gram-positive (GP) bacterial DNA, and the antibiotic-resistance gene bl

210 tervention) with usual general practitioner (GP) care (control).

211 datasets, we examined general practitioner (GP) consultations (visits) and emergency hospital admiss

212 ns with confirmed RSV, general practitioner (GP) data on attendance for care from acute respiratory i

213 3) were recruited from general practitioner (GP) practices in Oxfordshire and randomly allocated to "

214 king clustering within general practitioner (GP) practices into account using multilevel modelling.

215 imited by shortages in general practitioner (GP) resources.

216 General practitioners (GPs) are lacking in allergy training.

217 In control screening, general practitioners (GPs) were given a teaching session on viral hepatitis an

218 rried out by sentinel general practitioners (GPs) who compile weekly reports based on the number of i

219 Providing general practitioners (GPs) with access to a genetic test to assess lifetime ri

220 al procedures done by general practitioners [GPs]) are having on the specialty; (3) explore how perio

221 g neural networks (NN) and Gaussian process (GP), we observe that NN provides excellent predictions.

222 etely tuning-free Bayesian Gaussian process (GP)-based approach for estimating dynamic variance compo

223 Previous work has used Gaussian processes (GPs) in order to achieve this, but these can not deal wi

224 ressor and DNA repair gene protein products (GP)s at the end of 4th week during 4-week intermittent f

225 teomes; these results can be used to profile GPs phylogenetically via an interactive viewer.

226 ped using strongly typed genetic programing (GP) to recommend an optimized analysis pipeline for the

227 (cytosol), increased to MHS levels, promoted GP phosphorylation.

228 nt reduction in the levels of tumor promoter GPs at the end of 4th week during 4-week intermittent fa

229 Genome Properties (GPs) define such functional entities as a series of step

230 The surface-exposed viral protein, GP, mediates membrane fusion and undergoes major structu

231 s known to interact with the SSP to regulate GP processing and membrane fusion, but its biological ro

232 nd after RTX injection in the anterior right GP (protocol 1, n=7).

233 Results Apnea increased anterior right GP activity, followed by clustered crescendo vagal burst

234 , left stellate ganglion, and anterior right GP were obtained before and during apnea, before and aft

235 Sensilla SBTII, GP, and three functional subtypes of SST (SST1, SST2, an

236 bola glycoprotein (GP) and with the secreted GP (sGP) form.

237 rted apparent affinities of hGal-3 for serum GPs and their N-glycans.

238 n galectin-3 (hGal-3C) and three human serum GPs, alpha-1-acid glycoprotein (AGP), haptoglobin phenot

239 Utilisation of psychiatric health services, GP services, and social markers were assessed after 1, 2

240 siRNA gene knockdown experiments, silencing GP-5, GRN, and MPO decreased PLTs.

241 tibodies upon stimulation with EBOV-specific GP and NP antigens.

242 dily accessible assay to engineer stabilized GP variants for antiviral vaccines and to discover and i

243 geted mutagenesis of BDBV223 to enhance SUDV GP recognition indicates that additional determinants of

244 me survivor but specificity-matured for SUDV GP binding affinity, as a candidate pan-ebolavirus thera

245 Of the mAbs tested, GP base-binding mAbs were more potent neutralizers and m

246 e present in tandem, providing evidence that GPs from different CAZy families may work sequentially t

247 The GP had the greatest amounts of SOC, total N (TN), and mi

248 fer activity, whereas antibodies against the GP chalice bowl and the fusion loop require FcgammaR eng

249 sting of acute respiratory infections at the GP.

250 k the binding of antibodies specific for the GP glycan cap, the GP1-GP2 interface, the mucin-like dom

251 apparent affinity ( K(a)) of the GBP for the GP is then measured using the competitive proxy ligand-E

252 Importantly, for the GP, this effect became stronger when the value saliency

253 strong support for viral migration from the GP to FCs without evidence of substantial viral dissemin

254 y released as free oligosaccharides from the GP, are screened against the GBP using ESI-MS to identif

255 for, not a source of, virus strains from the GP.

256 rs was shorter in FCs (5 months) than in the GP (4 years).

257 at a genetic distance (GD) <1.5% than in the GP (Fisher's exact test, p = 0.001).

258 sion in FCs is isolated from networks in the GP.

259 egation of the CC and LC is dependent on the GP and OP identity factors PopZ and PodJ, respectively.

260 EBOV-520 targeted a conserved epitope on the GP base region.

261 central cavity and a hydrophilic rim on the GP, as observed for the m102.3-HeV co-crystal, albeit wi

262 targeting membrane proximal epitopes or the GP mucin domain do not rely on Fc-FcgammaR interactions

263 Our findings suggest that the GP and Th in humans are part of a subcortical executive

264 and LC exhibit abnormal localization to the GP at the beginning of the cell cycle and replicate from

265 n; post replication one copy migrates to the GP prior to division.

266 ce of substantial viral dissemination to the GP.

267 adiologists (radiologists 1 and 2) using the GP method.

268 ASD group with early onset compared with the GP group, with an adjusted odds ratio of 1.97 (95% confi

269 3, an m102.4 derivative, in complex with the GP of the related Hendra Virus (HeV) has been solved, th

270 eening the N-glycan libraries of each of the GPs against hGal-3C identified ligands corresponding to

271 information from records, patients and their GPs.

272 Despite these differences, all of these GPs displayed reduced thermostability upon cleavage to G

273 Adults presenting to these GPs with LBP as their primary complaint were recruited.

274 ormed, which included analysis of binding to GP, neutralization of individual ebolaviruses, epitope s

275 yed reduced thermostability upon cleavage to GP conformers (GP(CL)).

276 fications received from the BCSP database to GP records.

277 ost EBOV proteins and affinity maturation to GP is associated with rapid decline in viral replication

278 In response to an unknown cellular trigger, GP undergoes conformational rearrangements that drive fu

279 nforces type constraints with strongly typed GP and enables the incorporation of FSS at the beginning

280 Here, we describe a new assay that uses GP-specific antibodies to measure GP thermostability und

281 The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mi

282 Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and

283 ion, virions traffic to late endosomes where GP is cleaved by host cysteine proteases.

284 While GP consensus-based antigens failed to elicit neutralizin

285 was identified in FDR children compared with GP children.

286 interleukin-6 (IL-6) and IL-8 compared with GP controls.

287 y is mediated by the direct interaction with GP.

288 ZEBOV-GP enzyme-linked immunosorbent assay (ELISA) geometric m

289 1 of 3 consistency lots of rVSVDeltaG-ZEBOV-GP (2 x 107 plaque-forming units [pfu]), high-dose 1 x 1

290 y results support continued rVSVDeltaG-ZEBOV-GP development.

291 e for the deployment of the rVSVDeltaG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available

292 ased postvaccination in all rVSVDeltaG-ZEBOV-GP groups by 28 days (>58-fold) and persisted through 24

293 increased by 28 days in all rVSVDeltaG-ZEBOV-GP groups, peaking at 18 months with no decrease through

294 Immune responses to rVSVDeltaG-ZEBOV-GP persisted to 24 months.

295 c sites of the experimental rVSVDeltaG-ZEBOV-GP vaccine and therapeutics.

296 The Merck rVSVDeltaG-ZEBOV-GP vaccine appeared to be safe and immunogenic among the

297 ation trial using the Merck rVSVDeltaG-ZEBOV-GP vaccine was initiated.

298 elope glycoprotein vaccine (rVSVDeltaG-ZEBOV-GP).

299 ed and were vaccinated with rVSVDeltaG-ZEBOV-GP.

300 % of vaccine recipients seroresponded (ZEBOV-GP ELISA, >=2-fold increase, titer >=200 EU/mL), with re